Concord Biotech shares reach all-time high; Antique Broking reiterates 'Buy' recommendation

From Google: 2024-09-05 04:26:10

Concord Biotech’s shares reached an all-time high, prompting Antique Broking to maintain its “Buy” recommendation. The stock price surged by 1.91% to Rs 931.40 on the BSE. Concord Biotech specializes in developing and manufacturing fermentation-based active pharmaceutical ingredients (APIs) for the healthcare industry. Antique Broking believes the company has strong growth potential.

Investors are optimistic about Concord Biotech’s future prospects, driving the stock price to new highs. Antique Broking’s reiterated “Buy” recommendation reflects confidence in the company’s ability to deliver strong results. The market response indicates positive sentiment towards Concord Biotech and its focus on fermentation-based APIs.

Concord Biotech’s latest achievement is driven by its commitment to innovation and quality in the pharmaceutical sector. The company’s strategic focus on fermentation-based APIs has positioned it for success in the healthcare industry. Investors are recognizing Concord Biotech’s potential for growth and value creation, leading to increased interest in its shares.

Antique Broking’s endorsement of Concord Biotech reinforces investor confidence in the company’s long-term performance. The positive outlook on the stock reflects both current success and future growth opportunities for Concord Biotech. The pharmaceutical firm’s continuous innovation and strategic approach are key factors driving its strong market position and investor appeal.



Read more at Google: Concord Biotech shares hit all time high; Antique Broking reiterates ‘Buy’ – Business Standard